

THE UN COMMISSION ON LIFE-SAVING COMMODITIES FOR WOMEN AND CHILDREN



The Maternal Health Technical Resource Team

Transition to Maternal Health Caucus

RHSC Annual Meeting, October 2016



Availability of Quality Maternal Health Products [AQMHP]

- 4 products were pre-qualified, 1 ERP, 3 submitted for PQ, 3 receiving support
 - Misoprostol 2 products PQed (Cipla/India &Acme/India); 1 ERP approved (China Resources Zizhu Pharm./China), 2 receiving support
 - Oxytocin- 1 product PQed (Grindeks/Latvia), 1 submitted for PQ,
 1 receiving support
 - Magnesium Sulfate: 1 product PQed (Inresa Arzneimittel GmbH/Germany), 2 producted submitted for PQ

- File submitted and accepted to modify WHO EML of MgSO4
 - "For injection: 0.5g/ mL in 2 mL ampoule; 0.5g/ mL in 10 mL ampoule (50% w/v)
- Storage conditions for oxytocin: a brief overview document
- Quality Procurement workshop successfully held in Kampala (9/2015)
 &Tunis (7/2016)
 - Uganda, Kenya, Tanzania, Malawi, Zambia and Zimbabwe attended Kampala workshop. Tunisia, Niger, Congo, Cameroon, Benin, Burkina Faso and Senegal attended Tunis workshop. Both workshops included procurement decision makers, regulators & MOH program staff.
 - Quantification and other tools were disseminated

Essential Medicines List

- Inclusion of life-saving commodities (misoprostol) in national EMLs:
 DRC, Sierra Leone
- Development of <u>EML Search</u> a searchable database of national EMLs
- Advocacy resource guide developed with information on the process of updating and revising national EMLs: Updating National EMLs: A Step-by-Step Advocacy Guide
- Information packages on each commodity in final stages of development

Oxytocin in the Cold Chain

- Facilitated development and dissemination of UNICEF/WHO Joint statement: Temperature Sensitive Health Products in the EPI Cold Chain
- Options Analysis and case studies completed in Ghana and Mali for inclusion of oxytocin in cold chain
- Ghana govt has committed to putting oxytocin in the cold chain. Mali in process but stalled
- Brief developed with guidance on how to integrate oxytocin in cold chain

Commodity Security

- MH Commodity Security (MHCS) Framework and White Paper developed
- Validation exercises with multiple relevant stakeholders conducted in 3 countries (Tanzania, Ethiopia, and Nigeria)
- MHCS brief developed, incorporating country feedback
- Developed webinar materials (slide deck and script) applying the MHCS framework to a fictional country case study and conducted webinar
- Translated webinar materials into Spanish and French to be adapted for use

Innovation

- 3 pill pack of misoprostol produced by manufacturer
- Research on rectal MgS04 conducted and determined non-viable option
- Study on use of Temperature Time Indicator (TTI) on oxytocin in Ghana completed by 10/2016

Guideline development and dissemination

- Developed a protocol, applied and adapted in 3 countries (Ethiopia, Tanzania and Uganda)
 - Identified strategies with stakeholders to overcome barriers to implement guidelines
 - Prioritized feasible implementation strategies
 - Technical and logistical support provided by WHO and GREAT Network to facilitate guidelines implementation at the country level

Guideline development and dissemination

- Provided continuous support to strengthen local research capacity in the science and practice of knowledge translation (KT) and implementation research (IR) – through GREAT Network seed grants
- Developed and offered online Practicing Knowledge Translation (PKT) course to in-country partners in collaboration with experts in KT and IR

Dissemination Activities

- Uganda and Tunis Quality Procurement Workshop was an opportunity to disseminate various tools and resources of the MHTRT, including quantification guidance
- Presented MHTRT panels at GMNH conference in Mexico City and RHSC annual membership meeting
- Flash drives with tools and resources from multiple TRTs distributed during workshop, conference and meeting
- **Tools and resources** uploaded on <u>lifesavingcommodities.org</u> and partners' websites
- Newly prequalified products (Cipla's misoprostol and Grindeks' oxytocin) were announced through the RHSC platform